Key Takeaways Gilead Sciences shares have appreciated approximately 35% year-over-year, with recent trading activity near $147.82. Biktarvy, the company’s leading HIV therapy, plus emerging p
Gilead Sciences stock (GILD) has advanced roughly 35% during the trailing twelve-month period. The equity closed its most recent session around $147.82, showing a modest intraday decline.
While this performance trails certain biotechnology peers, the pharmaceutical maker’s core operations demonstrate consistent momentum. Its HIV product portfolio continues expanding, and recently launched therapies are contributing meaningful revenue.
The blockbuster HIV medication Biktarvy delivered $3.8 billion in quarterly revenue, representing substantial volume for an individual pharmaceutical product with continued year-over-year acceleration.
Yeztugo, the company’s recently approved prophylactic option, contributed to pushing its therapeutic category beyond the $1 billion sales milestone for the first time—an impressive achievement for a newly commercialized treatment.
Gilead’s latest quarterly disclosure arrived on August 3rd. The biopharmaceutical firm reported an adjusted loss of $6.75 per share, surpassing Wall Street’s consensus estimate of a $7.25 loss.
Total revenue reached $7.8 billion, exceeding the $7.4 billion projection from the analyst community. This figure represents a 10.6% increase compared to the corresponding period in the prior year.
Management subsequently increased its full-year revenue projection to between $30.1 billion and $30.4 billion. Several equity researchers suggest the company may be adopting a conservative stance with this guidance.
Shareholders receive a quarterly cash distribution of $0.82 per share, translating to an annual yield of 2.2%. The most recent payment was distributed on September 29th.
The investment community remains largely constructive on Gilead’s prospects. Twenty-three analysts currently maintain Buy recommendations, with six assigning Hold ratings. This consensus translates to a “Moderate Buy” outlook, with the average twelve-month price projection at $158.78.
Morgan Stanley modestly lowered its target to $165 while retaining an “overweight” stance. Needham & Company established a more optimistic $170 objective, maintaining its Buy recommendation.
However, not all institutional investors are adding exposure. Confluence Investment Management decreased its stake by 5% during the third quarter, liquidating approximately 41,000 shares. The investment manager maintains nearly 791,300 shares valued at roughly $117.9 million.
Corporate executives have been net sellers recently. Chief Executive Daniel O’Day disposed of 15,000 shares in early September at an average execution price of $148.64, realizing proceeds exceeding $2.2 million.
Executive Johanna Mercier sold 28,000 shares during August at $137.64 per share. Collectively, company insiders have divested 90,000 shares totaling approximately $12.7 million during the past ninety days.
Notwithstanding these transactions, institutional shareholders maintain substantial positions. Institutional entities collectively control nearly 84% of outstanding shares.
Regarding pipeline developments, Gilead is advancing a once-weekly HIV regimen created in partnership with Merck. This investigational therapy could receive regulatory clearance within the next several months, potentially strengthening its HIV franchise further.
The stock currently trades at approximately 15 times projected next-year earnings. This valuation appears reasonable relative to biotechnology sector norms, particularly given earnings per share forecasts reaching $10.66 by 2028.
Outstanding debt has expanded following recent corporate acquisitions, while pharmaceutical pricing dynamics remain an industry-wide consideration. Technical indicators show the 50-day moving average at $142.99, with the 200-day average positioned at $136.47.
The stock has fluctuated between $108.46 and $157.29 over the past fifty-two weeks. Current market capitalization stands at $183.29 billion.
The post Biktarvy Drives Gilead Sciences (GILD) Revenue to $7.8 Billion in Latest Quarter appeared first on Blockonomi.
